drugset
Drugs / New donor-derived CD7 CAR T-cell
last change Apr 2026 re-read 3 minutes ago

New donor-derived CD7 CAR T-cell

Cell therapy targets CD7

Developed for
T-cell acute lymphoblastic leukemia · T-cell and NK-cell neoplasm
Investigated by
Beijing GoBroad Hospital · Central People's Hospital of Zhanjiang · First Affiliated Hospital of Guangxi Medical University · Shanghai Liquan Hospital · The General Hospital of Western Theater Command · Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai

Trials 1

today NCT06316427 · Ph 1/2
20252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT06316427 Mar 2024 → Apr 2026 overdue T-cell acute lymphoblastic leukemia, T-cell and NK-cell neoplasm Beijing GoBroad Hospital Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as New donor-derived CD7 CAR T-cell ClinicalTrials.gov intervention name — accepted as the source's own label NCT06316427 ↗
Modality Cell therapy “New donor-derived CD7 CAR T-cell treatment” NCT06316427 ↗
Target CD7 “CD7 CAR T-cell” NCT06316427 ↗